Meeting
2015 ASCO Annual Meeting
Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102.
Authors
E. Gabriela Chiorean
University of Washington, Seattle, WA
E. Gabriela Chiorean , Joel Picus , Timothy Breen , Rafat H. Ansari , Wael A. Harb , Matthew Burns , Aaron John Spittler , Patrick J. Loehrer Sr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00522665
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3618)
DOI
10.1200/jco.2015.33.15_suppl.3618
Abstract #
3618
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest
Poster
2011 ASCO Annual Meeting
A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).
First Author: A. R. Townsend
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs